首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery

【24h】

Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery

机译：NRG-BR005的初步分析，II期试验评估肿瘤床活组织检查预测临床/放射性化疗后临床/放射性完全反应（NCT）患者病理完全反应（PCR）进行病理完全反应（NCT），探讨无手术治疗哺乳治疗的可行性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献

1. Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：NRG-BR005的初步分析，II期试验评估肿瘤床活组织检查预测临床/放射性化疗后临床/放射性完全反应（NCT）患者病理完全反应（PCR）进行病理完全反应（NCT），探讨无手术治疗哺乳治疗的可行性
2. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment) [J] . van der Noordaa M. E. M., van Duijnhoven F. H., Loo C. E., The Breast : . 2018,第期

机译：鉴定乳房后乳房的病理完全反应在具有超声引导的活组织检查最终省略手术中的乳房治疗：微米试验的研究和可行性（微创完整响应评估）
3. Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: A sub-study of EORTC 10994/BIG 1-00 phase III trial [J] . Fei F., Messina C., Slaets L., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2015,第3期

机译：肿瘤大小是可手术的或局部晚期乳腺癌的患者对新辅助化疗进行病理完全反应后远距离复发的唯一预测因素：EORTC 10994 / BIG 1-00 III期临床研究
4. Using Preoperative Mri-guided Biopsies to Predict Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer [D] . Kim, Jiyoon. 2019

机译：在乳腺癌新辅助化疗后使用术前Mri引导的活检来预测病理完全缓解
5. Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with completeear complete clinical and radiological response (Complete Responders in the Breast – CRBr) – Trial design and conduct [O] . N. Hariharan, T.S. Rao, S. Rajappa, 2019

机译：核心活检在预测具有完全/接近完全临床和放射学反应（乳房完全反应者– CRBr）的患者中乳房的病理完全反应中的准确性–试验设计和实施
6. Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr) – Trial design and conduct [O] . N. Hariharan, T.S. Rao, S. Rajappa, 2019

机译：核心活组织检查预测乳腺癌患者的病理完全反应的准确性（完整临床和放射响应（乳房CRBR中的完整响应者） - 试验设计和行为

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号